On February 10, 2025, Roivant Sciences reported its financial results for the third quarter ended December 31, 2024. The company announced consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately $5.2 billion as of the quarter's end. This strong cash position provides a substantial runway for its ongoing operations and pipeline development.
Roivant's Q3 revenue reached $9.02 million, surpassing analyst estimates of $5 million. The company also reported earnings per share (EPS) of $0.23, which was significantly better than the predicted loss of $0.25 per share. This performance indicates effective financial management and strategic momentum.
Research and development (R&D) expenses increased by $33.4 million to $141.6 million compared to $108.1 million in the prior year's quarter, driven by program-specific costs, particularly for the anti-FcRn franchise. Income from discontinued operations, net of tax, was $327.0 million, reflecting the gain on the sale of Dermavant to Organon in October 2024. Loss from continuing operations, net of tax, was $208.9 million, compared to income of approximately $5.1 billion in the prior year, which included the Telavant gain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.